Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

June 28, 2010 updated by: AstraZeneca
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

829

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
      • Daegu, Korea, Republic of
        • Research Site
      • Daejeon, Korea, Republic of
        • Research Site
      • Gwangju, Korea, Republic of
        • Research Site
      • Incheon, Korea, Republic of
        • Research Site
      • Jeju, Korea, Republic of
        • Research Site
      • Pusan, Korea, Republic of
        • Research Site
      • Seoul, Korea, Republic of
        • Research Site
      • Ulsan, Korea, Republic of
        • Research Site
    • Chungcheongbuk-do
      • Cheongju-si, Chungcheongbuk-do, Korea, Republic of
        • Research Site
      • Chungju-si, Chungcheongbuk-do, Korea, Republic of
        • Research Site
    • Chungcheongnam-do
      • Cheonan-si, Chungcheongnam-do, Korea, Republic of
        • Research Site
    • Gangwon-do
      • Gangneung-si, Gangwon-do, Korea, Republic of
        • Research Site
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Guri-si, Gyeonggi-do, Korea, Republic of
        • Research Site
    • Gyeongsangbuk-do
      • Gumi-si, Gyeongsangbuk-do, Korea, Republic of
        • Research Site
      • Gyeongju-si, Gyeongsangbuk-do, Korea, Republic of
        • Research Site
    • Gyeongsangnam-do
      • Masan-si, Gyeongsangnam-do, Korea, Republic of
        • Research Site
    • Jeollabuk-do
      • Iksan-si, Jeollabuk-do, Korea, Republic of
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Probability Sample

Study Population

Korean prostate cancer patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Description

Inclusion Criteria:

  • pathologic confirmation of prostate cancer
  • patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion Criteria:

  • patients who are hard to be analysed by limitation of chart record according to investigators'discretion
  • patients who already have been registered in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.

Secondary Outcome Measures

Outcome Measure
To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Study Director: Joon Woo Bahn, MD, AstraZeneca Korea

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2009

Primary Completion (Actual)

March 1, 2010

Study Completion (Actual)

March 1, 2010

Study Registration Dates

First Submitted

December 1, 2009

First Submitted That Met QC Criteria

December 2, 2009

First Posted (Estimate)

December 3, 2009

Study Record Updates

Last Update Posted (Estimate)

June 30, 2010

Last Update Submitted That Met QC Criteria

June 28, 2010

Last Verified

June 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-OKR-CAS-2009/1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe